Pulse Biosciences vs RenovoRx
PLSE and RNXT side by side, both in surgical, medical, and dental instruments and supplies. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How PLSE and RNXT compare
Pulse Biosciences is the larger company, worth 74 times as much as RenovoRx ($4.1B against $55.1M).
RenovoRx keeps more of each dollar of sales as profit, with a net margin of −469% compared with −5604% at Pulse Biosciences.
Pulse Biosciences scores higher on the StockData Score (8 against 6 for RenovoRx), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | PLSE | RNXT |
|---|---|---|
| Size and price | ||
| Market cap | $4.1B | $55.1M |
| Share price | $56.98 | $1.22 |
| Change, 1 year | 271% | 22.5% |
| Change, 5 years | 167% | −81.5% |
| Beta (5Y) | 1.26 | 1.32 |
| Employees | 116 | 17 |
| StockData Score | ||
| Total score | 8 (better) | 6 |
| Valuation score | 0 | 0 |
| Growth score | 2 (better) | 1 |
| Performance score | 0 | 0 |
| Health score | 6 (better) | 5 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 2720× | 19.8× (better) |
| P/B | 22.1× | 5.9× (better) |
| FCF yield | −1.6% (better) | −22.2% |
| Fair value | – | $0.464 |
| Margin of safety | – | −163% |
| Growth | ||
| Revenue growth (TTM) | 1637% | – |
| Profitability | ||
| Gross margin | 26.8% | 84.0% (better) |
| Operating margin | −5821% | −489% (better) |
| Net margin | −5604% | −469% (better) |
| FCF margin | −4264% | −440% (better) |
| Return on equity | −60.6% (better) | −150% |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Current ratio | 14.35 (better) | 5.65 |
| Altman Z-score | 131.35 (better) | −0.01 |
| Piotroski F-score | 3 | 4 (better) |
| Dividends and buybacks | ||
| Buyback yield | – | −18.2% |
| Shareholder yield | 0.00% (better) | −18.2% |
| Ownership | ||
| Held by institutions | 15.0% | 20.4% |
| Held by insiders | 71.2% | 6.0% |
| Insider net buying, 12 months | $23.9M (better) | $66.9K |
| Short interest, % of float | 14.1% | 2.4% |
Go deeper
- PLSE stock overview
- PLSE income statement
- PLSE valuation and score
- RNXT stock overview
- RNXT income statement
- RNXT valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.